Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 111

1.

Tuberculosis: advances and challenges in development of new diagnostics and biomarkers.

Walzl G, McNerney R, du Plessis N, Bates M, McHugh TD, Chegou NN, Zumla A.

Lancet Infect Dis. 2018 Jul;18(7):e199-e210. doi: 10.1016/S1473-3099(18)30111-7. Epub 2018 Mar 23. Review.

PMID:
29580818
2.

Tuberculosis.

Bloom BR, Atun R, Cohen T, Dye C, Fraser H, Gomez GB, Knight G, Murray M, Nardell E, Rubin E, Salomon J, Vassall A, Volchenkov G, White R, Wilson D, Yadav P.

In: Holmes KK, Bertozzi S, Bloom BR, Jha P, editors. Major Infectious Diseases. 3rd edition. Washington (DC): The International Bank for Reconstruction and Development / The World Bank; 2017 Nov 3. Chapter 11.

3.

New tuberculosis diagnostics and rollout.

McNerney R, Cunningham J, Hepple P, Zumla A.

Int J Infect Dis. 2015 Mar;32:81-6. doi: 10.1016/j.ijid.2015.01.012. Review.

4.

Delayed diagnosis and treatment of tuberculosis in HIV+ patients in Mozambique: A cost-effectiveness analysis of screening protocols based on four symptom screening, smear microscopy, urine LAM test and Xpert MTB/RIF.

Orlando S, Triulzi I, Ciccacci F, Palla I, Palombi L, Marazzi MC, Giuliano M, Floridia M, Mancinelli S, Mutemba E, Turchetti G.

PLoS One. 2018 Jul 19;13(7):e0200523. doi: 10.1371/journal.pone.0200523. eCollection 2018.

5.

Evaluation of the Xpert® MTB/RIF assay and microscopy for the diagnosis of Mycobacterium tuberculosis in Namibia.

Mavenyengwa RT, Shaduka E, Maposa I.

Infect Dis Poverty. 2017 Jan 11;6(1):13. doi: 10.1186/s40249-016-0213-y.

6.

Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults.

Steingart KR, Sohn H, Schiller I, Kloda LA, Boehme CC, Pai M, Dendukuri N.

Cochrane Database Syst Rev. 2013 Jan 31;(1):CD009593. doi: 10.1002/14651858.CD009593.pub2. Review. Update in: Cochrane Database Syst Rev. 2014;(1):CD009593.

7.

[Treatment and diagnostics of tuberculosis: moving slowly forward].

Andersen AB, Lillebæk T, Bang D, Prahl J.

Ugeskr Laeger. 2011 Mar 21;173(12):897-9. Danish.

PMID:
21419061
8.

Lateral flow urine lipoarabinomannan assay for detecting active tuberculosis in HIV-positive adults.

Shah M, Hanrahan C, Wang ZY, Dendukuri N, Lawn SD, Denkinger CM, Steingart KR.

Cochrane Database Syst Rev. 2016 May 10;(5):CD011420. doi: 10.1002/14651858.CD011420.pub2. Review.

9.

Tuberculosis diagnostics and biomarkers: needs, challenges, recent advances, and opportunities.

McNerney R, Maeurer M, Abubakar I, Marais B, McHugh TD, Ford N, Weyer K, Lawn S, Grobusch MP, Memish Z, Squire SB, Pantaleo G, Chakaya J, Casenghi M, Migliori GB, Mwaba P, Zijenah L, Hoelscher M, Cox H, Swaminathan S, Kim PS, Schito M, Harari A, Bates M, Schwank S, O'Grady J, Pletschette M, Ditui L, Atun R, Zumla A.

J Infect Dis. 2012 May 15;205 Suppl 2:S147-58. doi: 10.1093/infdis/jir860. Epub 2012 Apr 10. Review.

PMID:
22496353
10.

Rapid molecular test for tuberculosis: impact of its routine use at a referral hospital.

Casela M, Cerqueira SMA, Casela TO, Pereira MA, Santos SQD, Pozo FAD, Freire SM, Matos ED.

J Bras Pneumol. 2018 Apr;44(2):112-117. doi: 10.1590/s1806-37562017000000201. Portuguese, English.

11.

Tuberculosis diagnostics in 2015: landscape, priorities, needs, and prospects.

Pai M, Schito M.

J Infect Dis. 2015 Apr 1;211 Suppl 2:S21-8. doi: 10.1093/infdis/jiu803. Review.

12.

Advances in tuberculosis diagnostics: the Xpert MTB/RIF assay and future prospects for a point-of-care test.

Lawn SD, Mwaba P, Bates M, Piatek A, Alexander H, Marais BJ, Cuevas LE, McHugh TD, Zijenah L, Kapata N, Abubakar I, McNerney R, Hoelscher M, Memish ZA, Migliori GB, Kim P, Maeurer M, Schito M, Zumla A.

Lancet Infect Dis. 2013 Apr;13(4):349-61. doi: 10.1016/S1473-3099(13)70008-2. Epub 2013 Mar 24. Review.

13.

Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study.

Boehme CC, Nicol MP, Nabeta P, Michael JS, Gotuzzo E, Tahirli R, Gler MT, Blakemore R, Worodria W, Gray C, Huang L, Caceres T, Mehdiyev R, Raymond L, Whitelaw A, Sagadevan K, Alexander H, Albert H, Cobelens F, Cox H, Alland D, Perkins MD.

Lancet. 2011 Apr 30;377(9776):1495-505. doi: 10.1016/S0140-6736(11)60438-8. Epub 2011 Apr 18.

14.

Evaluation of the Xpert MTB/RIF assay for diagnosis of tuberculosis and rifampin resistance in county-level laboratories in Hunan province, China.

Hu P, Bai L, Liu F, Ou X, Zhang Z, Yi S, Chen Z, Gong D, Liu B, Guo J, Tan Y.

Chin Med J (Engl). 2014;127(21):3744-50.

PMID:
25382330
15.

[Development of antituberculous drugs: current status and future prospects].

Tomioka H, Namba K.

Kekkaku. 2006 Dec;81(12):753-74. Review. Japanese.

PMID:
17240921
16.

Do high rates of empirical treatment undermine the potential effect of new diagnostic tests for tuberculosis in high-burden settings?

Theron G, Peter J, Dowdy D, Langley I, Squire SB, Dheda K.

Lancet Infect Dis. 2014 Jun;14(6):527-32. doi: 10.1016/S1473-3099(13)70360-8. Epub 2014 Jan 15.

PMID:
24438820
17.

Performance of the Xpert MTB/RIF assay in the diagnosis of tuberculosis in formalin-fixed, paraffin-embedded tissues.

Polepole P, Kabwe M, Kasonde M, Tembo J, Shibemba A, O'Grady J, Kapata N, Zumla A, Bates M.

Int J Mycobacteriol. 2017 Jan-Mar;6(1):87-93. doi: 10.4103/2212-5531.201892.

18.

Impact of replacing smear microscopy with Xpert MTB/RIF for diagnosing tuberculosis in Brazil: a stepped-wedge cluster-randomized trial.

Durovni B, Saraceni V, van den Hof S, Trajman A, Cordeiro-Santos M, Cavalcante S, Menezes A, Cobelens F.

PLoS Med. 2014 Dec 9;11(12):e1001766. doi: 10.1371/journal.pmed.1001766. eCollection 2014 Dec. Erratum in: PLoS Med. 2015 Dec;12(12):e1001928.

19.

Intensified tuberculosis case-finding in HIV-positive adults managed at Ethiopian health centers: diagnostic yield of Xpert MTB/RIF compared with smear microscopy and liquid culture.

Balcha TT, Sturegård E, Winqvist N, Skogmar S, Reepalu A, Jemal ZH, Tibesso G, Schön T, Björkman P.

PLoS One. 2014 Jan 22;9(1):e85478. doi: 10.1371/journal.pone.0085478. eCollection 2014.

20.

Assessment of the sensitivity and specificity of Xpert MTB/RIF assay as an early sputum biomarker of response to tuberculosis treatment.

Friedrich SO, Rachow A, Saathoff E, Singh K, Mangu CD, Dawson R, Phillips PP, Venter A, Bateson A, Boehme CC, Heinrich N, Hunt RD, Boeree MJ, Zumla A, McHugh TD, Gillespie SH, Diacon AH, Hoelscher M; Pan African Consortium for the Evaluation of Anti-tuberculosis Antibiotics (PanACEA).

Lancet Respir Med. 2013 Aug;1(6):462-70. doi: 10.1016/S2213-2600(13)70119-X. Epub 2013 Jul 1.

Supplemental Content

Support Center